Galderma U.S. Initiates Six New Studies, Increasing Company's Commitment to Aesthetic Research and Innovation
October 11, 2018
FORT WORTH, Texas, Oct. 11, 2018 - Galderma Laboratories, L.P., a global leader focused on meeting the world's increasing skin health needs, has significantly increased its investment in research and innovation, initiating six new Phase III and IV U.S. aesthetic clinical trials.
"We are shaping the ever-evolving aesthetics industry like never before by developing new solutions to help drive consumers into aesthetic offices," said Alisa Lask, General Manager & Vice President of the U.S. Aesthetic Business at Galderma.